Bone Biologics Files Routine 8-K; No Major New Events Reported
Ticker: BBLGW · Form: 8-K · Filed: Jan 2, 2024 · CIK: 1419554
| Field | Detail |
|---|---|
| Company | Bone Biologics Corp (BBLGW) |
| Form Type | 8-K |
| Filed Date | Jan 2, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: corporate-governance, routine-filing
TL;DR
**BBLG filed a routine 8-K with no new material events, suggesting business as usual.**
AI Summary
Bone Biologics Corp. (BBLG) filed an 8-K on January 2, 2024, reporting that the earliest event occurred on December 27, 2023. This filing is a standard current report under Section 13 or 15(d) of the Securities Exchange Act of 1934, indicating no major new events like executive changes or compensatory arrangements, despite those being listed as potential item information. For investors, this means there's no immediate news of significant operational or leadership shifts that would typically impact stock price, suggesting a period of stability or lack of material developments to report.
Why It Matters
This filing indicates a lack of new material events, which can be interpreted as either stability or a lack of significant progress, depending on an investor's perspective on the company's current stage.
Risk Assessment
Risk Level: low — The filing itself is routine and does not introduce new risks or significant changes to the company's operations or leadership.
Analyst Insight
A smart investor would note the lack of new material information in this 8-K and continue to monitor for future filings that might contain more impactful news regarding operational changes, financial results, or strategic developments.
Key Players & Entities
- Bone Biologics Corp. (company) — the registrant filing the 8-K
- BBLG (company) — trading symbol for common stock
- BBLGW (company) — trading symbol for warrants
- The Nasdaq Stock Market LLC (company) — exchange where securities are registered
FAQ
What is the purpose of this 8-K filing by Bone Biologics Corp.?
This 8-K filing is a 'Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934,' indicating it's a standard disclosure for material events. However, the content provided does not detail any specific new material events, suggesting it's a routine update without significant new information.
What was the earliest event reported in this 8-K filing?
The 'Date of Report (Date of earliest event reported)' is December 27, 2023.
What are the trading symbols for Bone Biologics Corp.'s securities registered on The Nasdaq Stock Market LLC?
The trading symbol for their Common stock, $0.001 par value per share, is BBLG, and for their Warrants to Purchase Common stock, $0.001 par value per share, it is BBLGW.
Where is Bone Biologics Corp.'s principal executive office located?
The principal executive office is located at 2 Burlington Woods Drive, Ste. 100, Burlington, MA 01803.
What is the state of incorporation for Bone Biologics Corp.?
Bone Biologics Corp. is incorporated in Delaware.
Filing Stats: 441 words · 2 min read · ~1 pages · Grade level 12.4 · Accepted 2024-01-02 17:15:36
Key Financial Figures
- $0.001 — nge on which registered Common stock, $0.001 par value per share BBLG The Nasdaq
Filing Documents
- form8-k.htm (8-K) — 39KB
- 0001493152-24-000132.txt ( ) — 251KB
- bblg-20231227.xsd (EX-101.SCH) — 4KB
- bblg-20231227_def.xml (EX-101.DEF) — 26KB
- bblg-20231227_lab.xml (EX-101.LAB) — 36KB
- bblg-20231227_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 02, 2024 BONE BIOLOGICS CORPORATION By: /s/ JEFFREY FRELICK Name: Jeffrey Frelick Title: Chief Executive Officer